In conclusion, PD-1, 4-1BB and VISTA provide useful immunotherapeutic targets in skin cancer, and their combined use, applied locally or systemically, could provide improved treatment options for cutaneous SCC into the future. Here, VSIR is linked to skin neoplasm.